TGFB1 and osteogenesis imperfecta: Thus, the SHN3-targeting gene therapy approach taken here is also anticipated to be complimentary to either established osteoanabolic or antiresorptive therapeutics or to emerging therapeutic approaches that specifically target the molecular pathogenesis of OI, such as anti TGF-β antibodies5,12.